Haematologica (Apr 2021)
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma
- Man Chun John Ma,
- Saber Tadros,
- Alyssa Bouska,
- Tayla Heavican,
- Haopeng Yang,
- Qing Deng,
- Dalia Moore,
- Ariz Akhter,
- Keenan Hartert,
- Neeraj Jain,
- Jordan Showell,
- Sreejoyee Ghosh,
- Lesley Street,
- Marta Davidson,
- Christopher Carey,
- Joshua Tobin,
- Deepak Perumal,
- Julie M. Vose,
- Matthew A. Lunning,
- Aliyah R. Sohani,
- Benjamin J. Chen,
- Shannon Buckley,
- Loretta J. Nastoupil,
- R. Eric Davis,
- Jason R. Westin,
- Nathan H. Fowler,
- Samir Parekh,
- Maher Gandhi,
- Sattva Neelapu,
- Douglas Stewart,
- Kapil Bhalla,
- Javeed Iqbal,
- Timothy Greiner,
- Scott J. Rodig,
- Adnan Mansoor,
- Michael R. Green
Affiliations
- Man Chun John Ma
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Saber Tadros
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Alyssa Bouska
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
- Tayla Heavican
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
- Haopeng Yang
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Qing Deng
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Dalia Moore
- Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE
- Ariz Akhter
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB
- Keenan Hartert
- Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE
- Neeraj Jain
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Jordan Showell
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Sreejoyee Ghosh
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Lesley Street
- Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB
- Marta Davidson
- Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB
- Christopher Carey
- Northern Institute for Research, Newcastle University, Newcastle upon Tyne, England
- Joshua Tobin
- Diamantina Institute, University of Queensland, QLD
- Deepak Perumal
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
- Julie M. Vose
- Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE
- Matthew A. Lunning
- Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE
- Aliyah R. Sohani
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- Benjamin J. Chen
- Department of Pathology, University of Massachusetts Medical School, UMass Memorial Medical Center, Worcester, MA
- Shannon Buckley
- Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE
- Loretta J. Nastoupil
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- R. Eric Davis
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Jason R. Westin
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Nathan H. Fowler
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Samir Parekh
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
- Maher Gandhi
- Diamantina Institute, University of Queensland, QLD
- Sattva Neelapu
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
- Douglas Stewart
- Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB
- Kapil Bhalla
- Department of Pathology, Brigham and Womens Hospital, Boston, MA
- Javeed Iqbal
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
- Timothy Greiner
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
- Scott J. Rodig
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
- Adnan Mansoor
- Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB
- Michael R. Green
- Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, Houston, TX
- DOI
- https://doi.org/10.3324/haematol.2020.274258
- Journal volume & issue
-
Vol. 107,
no. 3
Abstract
B-cell non-Hodgkin lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL, such as diffuse large B-cell lymphoma, have been comprehensively interrogated at the genomic level, but rarer subtypes, such as mantle cell lymphoma, remain less extensively characterized. Furthermore, multiple B-NHL subtypes have thus far not been comprehensively compared using the same methodology to identify conserved or subtype-specific patterns of genomic alterations. Here, we employed a large targeted hybrid-capture sequencing approach encompassing 380 genes to interrogate the genomic landscapes of 685 B-NHL tumors at high depth, including diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and Burkitt lymphoma. We identified conserved hallmarks of B-NHL that were deregulated in the majority of tumors from each subtype, including frequent genetic deregulation of the ubiquitin proteasome system. In addition, we identified subtype-specific patterns of genetic alterations, including clusters of co-occurring mutations and DNA copy number alterations. The cumulative burden of mutations within a single cluster were more discriminatory of B-NHL subtypes than individual mutations, implicating likely patterns of genetic cooperation that contribute to disease etiology. We therefore provide the first cross-sectional analysis of mutations and DNA copy number alterations across major B-NHL subtypes and a framework of co-occurring genetic alterations that deregulate genetic hallmarks and likely cooperate in lymphomagenesis.